Table 1. Characteristics of studies included in the meta-analysis.
| Ref | Patient No. | Age, median (range) | Male/Female | Stage | Follow-up, median (range) | Marker | Tissue Distribution | Cutoff value | Antibody (Clone) | NOS Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Studies including OS | ||||||||||
| Carus, A., et al. (2013) | 335 | ≥65, 200; <65, 135 | 194/141 | I–IIIA | NR | CD163 | Tumor islet | ≥0.21% of tissue area | Anti-CD163(EDHu-1) | 7 |
| Tumor stroma | ≥2.19% of tissue area | |||||||||
| Chen, J. J., et al. (2003) | 35 | 60.3 | 24/11 | I–IIIA | NR | CD68 | Tumor islet and stroma | ≥162 cells/field (200×) | Anti-CD68(NR) | 7 |
| Dai, Fuqiang., et al. (2010) | 99 | 60 (37 – 80) | 80/19 | I-IV | 96 | CD68 | Tumor islet and stroma | ≥15 cells/field (400×) | Anti-CD68(KP1) | 8 |
| Tumor islet | ||||||||||
| Tumor stroma | ||||||||||
| Tumor islet/stroma | ||||||||||
| Hirayama, S., et al. (2012) | 208 | 69 (46–88) | 188/20 | I-IIIA | 68.4 | CD204 | Tumor stroma | ≥30 cells/field(400×) | Anti-CD204(A-E5) | 8 |
| Tumor islet | ≥9 cells/field (400×) | |||||||||
| Ho, C. C., et al. (2008) | 68 | NR | 40/28 | I-III | 41 | TREM-1 | Tumor islet and stroma | ≥15 cells/field (400×) | Anti-TREM-1(AF1278) | 7 |
| Kawai, O., et al. (2008) | 199 | 62 (39-79) | 139/60 | IV | NR | CD68 | Tumor islet/stroma | ≥1 | Anti-CD68(NR) | 7 |
| Tumor islet | ≥13 cells/field (400×) | |||||||||
| Tumor stroma | ≥12 cells/field (400×) | |||||||||
| Kim, D. W., et al. (2008) | 144 | 60.4 | 106/38 | IA-IV | NR | CD68 | Tumor stroma | ≥233 cells/mm2 (400×) | Anti-CD68(M0876) | 7 |
| Tumor islet | ≥28 cells/mm2 (400×) | |||||||||
| Li, Y., et al. (2015) | 159 | 61 (44-77) | 109/50 | I-III | 46 (2-120) | CD68 | Tumor islet and stroma | NR | Anti-CD68(ED1) | 8 |
| Osteopontin/CD68 | Tumor islet and stroma | NR | Anti-OPN(NR); Anti-CD68(KP1) | |||||||
| Ma, J., et al. (2010) | 100 | NR | 81/19 | I-IV | Max 96 | CD68/HLA-DR | Tumor islet and stroma | NR | Anti-CD68(KP1); Anti-HLA-DR(LN3) | 7 |
| Tumor islet | NR | |||||||||
| Tumor stroma | NR | |||||||||
| CD68/CD163 | Tumor islet and stroma | NR | Anti-CD68(KP1); Anti-CD163(10D6) | |||||||
| Tumor islet | NR | |||||||||
| Tumor stroma | NR | |||||||||
| Ohtaki, Y., et al. (2010) | 170 | 62 (33–85) | 85/85 | IA-IIIA | 121.2 | CD68 | Tumor islet | 25 cells/mm2 (400×) | Anti-CD68(NR) | 8 |
| CD204 | Tumor stroma | 15 cells/mm2 (400×) | Anti-CD204(A-E5) | |||||||
| Pei, B.-x., et al. (2014) | 417 | NR | 231/186 | I-III | 43 (2-120) | CD68 | Tumor stroma | positive of CD68+ cells | Anti-CD68(KP1) | 7 |
| Takahashi, A., et al. (2013) | 115 | 68 (22-86) | 98/17 | IA-IV | 52.8 | CD204 | Tumor islet and stroma | ≥20 cells/field (400×) | Anti-CD204(A-E5) | 8 |
| Takanami, I., et al. (1999) | 113 | 62 (30-79) | 66/47 | I-IV | NR | CD68 | Tumor islet and stroma | Densities> 32 | Anti-CD68(KP1) | 7 |
| Welsh, T. J., et al. (2005) | 162 | NR | NR | I-IV | NR | CD68 | Tumor islet | ≥131 cells/mm2 (200×) | Anti-CD68(PGM1) | 6 |
| Tumor stroma | ≥174 cells/mm2 (200×) | |||||||||
| Tumor islet/stroma | ≥Median value | |||||||||
| Zeni, E., et al. (2007) | 47 | 63.9 | 43/7 | I-IV | NR | IL-10/CD68 | Tumor islet and stroma | ≥16.3% of tissue area | Anti-IL-10(NR); Anti-CD68(M0814) | 7 |
| Zhang, B., et al. (2011) | 65 | NR | 38/27 | I-IV | NR | CD68 | Tumor islet and stroma | ≥102 cells/field (100×) | Anti-CD68(NR) | 6 |
| CD68/CD206 | Tumor islet and stroma | ≥82 cells/field (100×) | ||||||||
| Zhang, W., et al. (2013) | 67 | 71(45-85) | 22/27 | I-III | 53.3 (2.1–201.7) | CD68 | Tumor islet and stroma | ≥50% of tissue area | Anti-CD68(514H12) | 8 |
| Studies including DFS | ||||||||||
| Chen, J. J., et al. (2003) | 35 | 60.3 | 24/11 | I–IIIA | NR | CD68 | Tumor islet and stroma | ≥162 cells/field (200×) | Anti-CD68(NR) | 7 |
| Hirayama, S., et al. (2012) | 208 | 69 (46–88) | 188/20 | I-IIIA | 68.4 | CD204 | Tumor stroma | ≥30 cells/field(400×) | Anti-CD204(A-E5) | 8 |
| Tumor islet | ≥9 cells/field (400×) | |||||||||
| Ho, C. C., et al. (2008) | 68 | NR | 40/28 | I-III | 41 | TREM-1 | Tumor islet and stroma | ≥15 cells/field (400×) | Anti-TREM-1(AF1278) | 7 |
| Ito, M., et al. (2012) | 304 | NR | 139/165 | I | 87(5-181) | CD204 | Tumor islet and stroma | ≥8 cells/field (400×) | Anti-CD204(A-E5) | 7 |
| Kaseda, K., et al. (2013) | 41 | NR | NR | I | NR | CD204 | Tumor stroma | NR | Anti-CD204(A-E5) | 6 |
| Li, Y., et al. (2015) | 159 | 61 (44-77) | 109/50 | I-III | 46 (2-120) | CD68 | Tumor islet and stroma | NR | Anti-CD68(ED1) | 8 |
| Osteopontin/CD68 | Tumor islet and stroma | NR | Anti-OPN(NR); Anti-CD68(KP1) | |||||||
| Maeda, R., et al. (2014) | 207 | NR | 94/113 | I | NR | CD204 | Tumor islet and stroma | ≥8 cells/field (400×) | Anti-CD204(A-E5) | 6 |
| Pei, B.-x., et al. (2014) | 417 | NR | 231/186 | I-III | 43 (2-120) | CD68 | Tumor stroma | positive of CD68+ cells | Anti-CD68(KP1) | 7 |
| Takahashi, A., et al. (2013) | 115 | 68 (22-86) | 98/17 | IA-IV | 52.8 | CD204 | Tumor islet and stroma | ≥20 cells/field (400×) | Anti-CD204(A-E5) | 8 |
NR: Not Reported; DFS: disease-free survival; OS: overall survival.